Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (12215)	11/12/1999 10:58:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

I have reason to believe the drug shows activity, its the utilization and understanding thats the key IMO. Lung and liver still on my mind. I dont think most of the folks here understand the need for a fungicidal. Likewise, it boggles my mind that angio seems so interesting with such heavy competition. What do they got? And anti-cd11a? appears so good, that we see expansion as multi indication also. I see no other pipeline that comes close. Its gonna be boom or bust. I can go on and on. Place your bets. standard K.